• Vivos won FDA clearance for a Feasibility IDE on July 22, 2026, enabling a first-in-human RadioGel study at Mayo Clinic in Florida.
• The trial targets non-resectable papillary thyroid carcinoma. Initial enrollment set at five patients to assess safety and feasibility.
• FDA cut the required safety follow-up to 24 months from five years, supporting faster planning for subsequent pivotal studies.
• In India, trials at HGC were paused during an internal audit. Approvals remain in place. DCGI restart decision expected by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270830PRIMZONEFULLFEED9798420) on July 27, 2026, and is solely responsible for the information contained therein.